ClinicalTrials.gg
CompletedNCT00327691TNTUpdated May 3, 2007

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

A Phase 4 interventional study of Atorvastatin in Cardiovascular Disease, Cerebrovascular Accident and Coronary Heart Disease, sponsored by Pfizer. Completed at 314 sites in 14 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-05-03.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,600
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

02

Conditions studied

  • Cardiovascular Disease
  • Cerebrovascular Accident
  • Coronary Heart Disease

Keywords

  • Major cardiovascular event
  • Major Coronary event
  • Revascularization
03

In context

Cardiovascular Diseases

5,372 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 8,600 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women age 35-75 who have evident CHD

Exclusion criteria

Exclusion Criteria:

Known to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
8,600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary outcome is the time to occurrence of a major

  2. cardiovascular event, defined as the composite outcome of the

  3. following clinical endpoints

  4. CHD death

  5. Non-fatal/Non-procedure related MI

  6. Resuscitated cardiac arrest or fatal/non-fatal stroke

Secondary outcomes

  1. The occurrence of the following clinical events

  2. Major coronary event (CHD death, non fatal myocardial infarction or resuscitated cardiac arrest)

  3. any coronary event (major coronary event or CABG

  4. PTCA, other revascularization procedure, procedure-related myocardial infarction, or documented angina)

  5. cerebrovascular event (fatal or non fatal stroke, TIA)

  6. peripheral vascular disease; hospitalization with primary diagnosis' of CHF

  7. any cardiovascular event (any of the above); and all-cause mortality.

07

Study locations

314 sites
  • Pfizer Investigational Site
    Alabaster, Alabama 35007, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35205-4785, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35213, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294-2041, United States
  • Pfizer Investigational Site
    Hoover, Alabama 35216, United States
  • Pfizer Investigational Site
    Montgomery, Alabama 36117, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85202, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85206, United States
  • Pfizer Investigational Site
    Burbank, California 91505, United States
  • Pfizer Investigational Site
    Camp Pendleton, California 92055, United States
  • Pfizer Investigational Site
    Fresno, California 93703, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    Loma Linda, California 92354, United States
  • Pfizer Investigational Site
    Los Angeles, California 90017-2395, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    Modesto, California 95350, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    San Diego, California 92134-3303, United States
  • Pfizer Investigational Site
    San Francisco, California 94143-0130, United States
  • Pfizer Investigational Site
    San Francisco, California 94143-0326, United States
  • Pfizer Investigational Site
    Santa Rosa, California 95403, United States
  • Pfizer Investigational Site
    Stanford, California, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Denver, Colorado 80203, United States
  • Pfizer Investigational Site
    Denver, Colorado 80218, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Bridgeport, Connecticut 06610, United States
  • Pfizer Investigational Site
    Hartford, Connecticut 06102, United States
  • Pfizer Investigational Site
    New Britain, Connecticut 06053, United States
  • Pfizer Investigational Site
    Newark, Delaware 19718, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20037, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33756, United States
  • Pfizer Investigational Site
    Gainsville, Florida 32608, United States
  • Pfizer Investigational Site
    Gainsville, Florida 32610, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Inverness, Florida 34452, United States
  • Pfizer Investigational Site
    Lakeland, Florida 33805, United States
  • Pfizer Investigational Site
    Miami, Florida 33173, United States
  • Pfizer Investigational Site
    Miami, Florida 33176, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Orlando, Florida 32803, United States
  • Pfizer Investigational Site
    Port Charlotte, Florida 33952, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34239, United States
  • Pfizer Investigational Site
    Stuart, Florida 34996, United States
  • Pfizer Investigational Site
    Tamarac, Florida 33321, United States
  • Pfizer Investigational Site
    The Villages, Florida 32159, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Canton, Georgia 30114, United States
  • Pfizer Investigational Site
    Berwyn, Illinois 60402, United States
  • Pfizer Investigational Site
    Blue Island, Illinois 60406, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60611, United States
  • Pfizer Investigational Site
    DuQuoin, Illinois 62832, United States
  • Pfizer Investigational Site
    Evanston, Illinois 60201, United States
  • Pfizer Investigational Site
    Lake Forest, Illinois 60045, United States
  • Pfizer Investigational Site
    Marion, Illinois 62959, United States
  • Pfizer Investigational Site
    Pekin, Illinois 61554, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61603, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61614, United States
  • Pfizer Investigational Site
    Beech Grove, Indiana 46107, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47710, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46805, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46825, United States
  • Pfizer Investigational Site
    Jeffersonville, Indiana 47130, United States
  • Pfizer Investigational Site
    Scottsburg, Indiana 47170, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50314, United States
  • Pfizer Investigational Site
    Iowa City, Iowa 52242, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160-7200, United States
  • Pfizer Investigational Site
    Lathe, Kansas 66061, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66213, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67220, United States
  • Pfizer Investigational Site
    Edgewood, Kentucky 41017, United States
  • Pfizer Investigational Site
    Erlanger, Kentucky 41018, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    Marrero, Louisiana 70072, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70121, United States
  • Pfizer Investigational Site
    Portland, Maine 04102, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21201, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21204, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21205, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21208, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21218, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21224, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21228, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21229, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21237, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    Bel Air, Maryland 21014, United States
  • Pfizer Investigational Site
    Westminster, Maryland 21157, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Burlington, Massachusetts 1805, United States
  • Pfizer Investigational Site
    Dearborn, Michigan 48126, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Farmington Hill, Michigan 48336, United States
  • Pfizer Investigational Site
    Sterling Heights, Michigan 48310, United States
  • Pfizer Investigational Site
    West Bloomfield, Michigan 48322, United States
  • Pfizer Investigational Site
    Duluth, Minnesota 55805, United States

Showing the first 100 of 314 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17. PubMed 17084252 ↗
  • Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827. PubMed 31020900 ↗
  • Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724. PubMed 30571333 ↗
  • Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5. PubMed 29622600 ↗
  • Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318. PubMed 29618599 ↗
  • Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387. PubMed 29358194 ↗
  • Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0. PubMed 28573499 ↗
  • Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148. PubMed 28379800 ↗
  • Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648. PubMed 28214794 ↗
  • Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30. PubMed 27513651 ↗
  • Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050. PubMed 25835440 ↗
  • Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014. PubMed 25531109 ↗
  • Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14. PubMed 23674398 ↗
  • Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524. PubMed 22576673 ↗
  • Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043. PubMed 22575316 ↗
  • Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29. PubMed 22461416 ↗
  • Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. doi: 10.1161/CIRCGENETICS.111.960252. Epub 2011 Dec 1. PubMed 22135385 ↗
  • Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052. PubMed 21185503 ↗
  • Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3. PubMed 20130232 ↗
  • Waters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502. doi: 10.1016/j.pcad.2009.01.001. PubMed 19410683 ↗
  • Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug;83(8):870-9. PubMed 18674471 ↗
  • Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054. PubMed 18482661 ↗
  • Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072. PubMed 18402899 ↗
  • Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278. PubMed 17898099 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1998 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2006
First posted
May 18, 2006
Start
Apr 1998
Completion
Aug 2004
Last update
May 3, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on May 3, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00327691
Lead sponsor
Pfizer
First posted
May 18, 2006
Start date
Apr 1998
Completion
Aug 2004
Last update
May 3, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion